Results 31 to 40 of about 81,723 (303)
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. [PDF]
, 2017 BackgroundLiposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease.
Doan, Ngan B +9 more
core +2 more sources
Regulation of anti-inflammatory gene expression in vascular endothelial cells by EPAC1 [PDF]
, 2015 Suppressor of cytokine signalling 3 (SOCS3) is a potent inhibitor of pro-inflammatory pathways involved in atherogenesis and the development of neo-intimal hyperplasia (NIH), which contributes to the in-stent re-stenosis responsible for the failure of ...
Palmer, Timothy P., Yarwood, Stephen J.
core +1 more source
Janus kinase inhibitors: between prescription authorization and reimbursability
Reumatismo, 2023 Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.
F.R. Spinelli +5 more
openaire +5 more sources
Primary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor
Case Reports in Nephrology and Dialysis, 2021 Extramedullary hematopoiesis is widely known to occur in patients with primary myelofibrosis (PMF). Autopsy studies on individuals with PMF revealed that extramedullary hematopoiesis occurred in the kidneys in 35% of the cases, but there is little ...
Mea Asou +5 more
doaj +1 more source
TYK2-induced phosphorylation of Y640 suppresses STAT3 transcriptional activity [PDF]
, 2017 STAT3 is a pleiotropic transcription factor involved in homeostatic and host defense processes in the human body. It is activated by numerous cytokines and growth factors and generates a series of cellular effects.
De Bosscher, Karolien +7 more
core +3 more sources
Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19
Brain Hemorrhages, 2021 Objectives: Intracerebral hemorrhage/bleeding (ICH) after an infection with SARS-CoV-2 (COVID-19) treated with the Janus-kinase inhibitor baricitinib has not been reported.
Josef Finsterer, Fulvio A. Scorza
doaj +1 more source
BMC Infectious Diseases, 2019 Background Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation.
Katya Prakash, Douglas Richman
doaj +1 more source
, 2016 Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel +2 more
core +1 more source
Nature Communications, 2021 Increased risk of premature cardiovascular disease in systemic lupus erythematosus (SLE) is not well understood, but in animal models, the Janus kinase inhibitor tofacitinib improves related phenotypes.
Sarfaraz A. Hasni +38 more
doaj +1 more source